Singapore Medical Device Registration: 26 Questions on HSA Routes, Fees and the Singapore-Malaysia-Thailand Reliance Network

Singapore’s Health Sciences Authority (HSA) runs one of the most predictable medical device regimes in Asia, and since 2025 its approval has become a gateway into Malaysia and Thailand as well. This FAQ answers 26 questions in the order an exporter actually meets them: who regulates, how devices are classified, which evaluation route applies, what it costs, who must hold the licence, and how the Singapore-Malaysia-Thailand reliance programmes can cut months off subsequent filings.

All figures and dates below are taken from HSA, Malaysia’s Medical Device Authority (MDA) and the Thai FDA – including the 2025 Singapore-Malaysia MOU, the Malaysia-Thailand programme that went fully live on 1 May 2026, and Thailand’s HSA Reliance Route.

1. Regulatory framework (Q1-Q3)

Q1. Who regulates medical devices in Singapore, and under which law?

The medical device branch of the Health Sciences Authority (HSA). The legal basis is the Health Products Act (HPA), the Health Products (Medical Devices) Regulations, and the GN-series guidance documents – notably GN-15 on product registration and GN-22 on Class A devices.

Approved products are listed on the Singapore Medical Device Register (SMDR). Listing is a precondition for lawful sale, except for Class A devices, which are exempt from registration.

Q2. What changed in the submission system in 2025?

Since July 2025 HSA has retired MEDICS and moved everything to SHARE (Singapore Health Product Access and Regulatory E-System). New registrations, Class A notifications, dealer licences, change notifications, Free Sale Certificates and Special Access Route (SAR) applications all go through SHARE, with companies logging in via Corppass.

SHARE also adds practical improvements: a more structured Class A notification, importer-linkage confirmation, the ability to set a future cancellation date, and automatic reminders 30 days before the retention fee falls due. Pending MEDICS applications were migrated – the point most often missed by companies that had not logged in for a while.

Q3. Why is Singapore the natural first stop for ASEAN?

1. Reference-agency standing: HSA was recognised by WHO in June 2023 as a Stringent Regulatory Authority for high-risk IVDs and reached maturity level ML4; in 2022 Australia’s TGA added it to the Comparable Overseas Regulators list alongside the US, EU, Canada and Japan.
2. Working reliance mechanisms: HSA approval is accepted by Malaysia’s MDA (Verification Route) and by the Thai FDA (Reliance Route), and Singapore-Malaysia and Thailand-Malaysia now both run formal bilateral programmes.
3. Language and predictability: applications are entirely in English, with no translation or notarisation requirement, and HSA publishes committed review timelines in working days for every route.

2. Risk classification (Q4-Q6)

Q4. How does Singapore classify medical devices?

HSA uses the four-tier GHTF/IMDRF system, aligned with the ASEAN Medical Device Directive (AMDD). Rules weigh contact duration (transient, short-term, long-term), invasiveness, whether the device is active, and intended use.

Q5. Do Class A products need registration?

No product registration – but not no obligations. Class A devices, including some sterile Class A, are exempt from SMDR listing on three conditions:

• They meet the essential safety and performance requirements of the HPA;
• The local dealer files a Class A notification or exemption declaration through SHARE;
• Technical documentation is retained for inspection – HSA runs post-market spot checks and can order non-compliant products off the market.

Q6. How are SaMD and AI-based devices classified?

Software is classified on the same A-D scale, driven by intended use and the risk of the clinical decision it supports; most software lands in Class B to D. Pure wellness apps with no diagnostic or therapeutic claim are not medical devices. HSA updated its SaMD and clinical decision support guidance (GL-07) in 2025: AI diagnostic software is graded by clinical risk, and use cases that directly drive treatment decisions can reach Class C or D.

3. Evaluation routes, fees and dossier (Q7-Q12)

Q7. Which evaluation routes exist for Class B, C and D devices?

There are four, and the choice depends on whether the device already holds approval from an HSA-recognised reference agency:

Note that some high-risk Class D devices – active implantables and devices implanted in the central nervous or central circulatory system – cannot use the expedited route.

Q8. Which reference agencies does HSA recognise?

1. US FDA;
2. EU notified bodies (CE under MDR or MDD);
3. Health Canada;
4. Australia TGA;
5. Japan PMDA/MHLW.

China’s NMPA is not on the list. A device holding only an NMPA certificate must go through the Full route. Malaysia MDA registration can, however, support an Abridged review under the Singapore-Malaysia programme (see section 5).

Q9. What are the review timelines and official fees?

Current HSA figures, in Singapore dollars, with timelines in working days excluding clock-stop time while the applicant responds to queries. The application fee is a flat S$560 for Class B, C and D.

A Priority Review Scheme can compress Class C Full to 143 days and Class D Full to 202 days, at a higher fee.

Q10. Are there annual fees after listing?

Yes. An annual retention fee keeps the SMDR listing alive: S$39 for Class B, S$67 for Class C and S$134 for Class D. Non-payment lapses the listing; SHARE sends an automatic reminder 30 days before the due date.

Q11. What format must the dossier follow?

The ASEAN Common Submission Dossier Template (CSDT). This is the hidden dividend of a Singapore filing: one CSDT can be reused in Malaysia, Thailand, Indonesia and the Philippines. The core content is:

• Administrative: application form, letter of authorisation (LOA), evidence of reference-agency approval, ISO 13485 certificate;
• Technical: device description and intended use, essential principles checklist, design verification and validation, biocompatibility, electrical safety and EMC (IEC 60601 series), software documentation (IEC 62304 plus cybersecurity), sterilisation validation, clinical evaluation report (CER), risk management (ISO 14971), and English labelling and instructions for use.

Q12. Is a clinical evaluation report mandatory for Class C and D?

Yes. Under both the Full and Abridged routes, Class C and D applications must include a CER as the core evidence of safety and performance. On the Abridged route HSA concentrates on clinical data and risk controls and may ask for Asia-specific data or additional biocompatibility detail.

4. Registrant, dealer licences and changes (Q13-Q17)

Q13. Can a foreign manufacturer register directly with HSA?

No. A Singapore-incorporated company must act as Registrant: it submits the SMDR application, handles all HSA correspondence, maintains technical documentation and change records, and carries post-market vigilance responsibility. The Registrant is the device’s regulatory responsible party in Singapore.

Q14. How do the Registrant and the Dealer’s Licence relate?

• Registrant: holds the product registration and is responsible for filings, HSA liaison, change notifications and adverse event reporting;
• Dealer’s Licence: three types – importer, wholesaler and manufacturer. Any entity importing, wholesaling or manufacturing in Singapore must hold the relevant licence; each costs S$1,110 per year and takes about 10 working days to obtain.

One Registrant may appoint several licensed importers or wholesalers for the same registered product in SHARE – the one-registrant, multiple-dealer model is expressly allowed.

Q15. What quality system must importers and wholesalers have?

Holders of importer or wholesaler licences for Class B, C and D devices must comply with GDPMDS (Good Distribution Practice for Medical Devices, SS 620). HSA accepts ISO 13485 or MDSAP certificates issued by bodies accredited by the Singapore Accreditation Council (SAC) as equivalent evidence.

Q16. Can a registration be transferred to another Registrant?

Yes, but it normally requires the incumbent Registrant’s cooperation and relinquishment. The change-of-registrant application costs S$880 with a 40-working-day review, and HSA has issued dedicated guidance (GN-24). The practical lesson: agree ownership and transfer mechanics of the certificate in the distribution contract before filing, or changing agent later becomes very difficult.

Q17. Must post-approval changes be notified to HSA?

Yes, through a Change Notification in SHARE (GN-21, sixth edition as of 2025). Fees and timelines depend on class and on whether the change is administrative or technical:

Major changes can trigger re-registration.

5. The Singapore-Malaysia-Thailand reliance network (Q18-Q25)

The word ‘mutual recognition’ is misleading here. As of October 2026 there are four distinct reliance mechanisms, differing in direction, scope and effect: two formal bilateral programmes (Singapore-Malaysia and Thailand-Malaysia), Thailand’s unilateral HSA Reliance Route, and Thailand’s reference-agency list. Confusing the direction of any of them produces a wrong registration strategy.

Q18. What exactly is the Singapore-Malaysia programme?

The first reciprocal reliance arrangement to land in ASEAN. Malaysia’s MDA and HSA signed an MOU on 22 August 2025 at the 14th ASEAN Medical Device Committee meeting in Siem Reap, launching the Medical Device Regulatory Reliance Programme. The pilot ran from 1 September 2025 to 28 February 2026; in March 2026 both sides confirmed it successful and made it a standing arrangement.

Scope: Class B, C and D devices. Excluded are products classified differently in the two countries and Class D devices with an ancillary medicinal product.

Q19. How does an HSA approval speed up Malaysian registration?

Through MDA’s Verification Route. An MDA-recognised conformity assessment body (CAB) performs an abridged review of about 30 working days instead of the 60 working days of the full conformity assessment, with registration following in roughly another 30 working days under MDA/GD/0070.

MDA’s list of recognised countries and agencies, updated by its second circular of October 2025 (which also revised MDA/GD/0068 and MDA/GD/0070), now covers eight: EU notified bodies, Japan MHLW, Australia TGA, Health Canada, US FDA, UK MHRA, Singapore HSA and Thai FDA. Singapore HSA and Thai FDA are the two additions. Malaysia is now one of the most open markets in ASEAN: any of these approvals can potentially substitute a CAB verification for the full conformity assessment.

One new rule to track in parallel: Malaysia’s ePermit import licensing for all registered devices, originally due in January 2026, has been postponed to July 2027. It requires one permit per shipment, applied for at least seven days before shipment, valid 90 days and covering up to 99 SKUs. A fast registration does not by itself mean goods can ship.

Q20. And the reverse – how does an MDA approval speed up Singapore registration?

In SHARE, select ‘Regulatory Reliance Program: Malaysia Medical Device Authority (MDA)’ among the Evaluation Route Determinants. The application is then assessed under the Abridged route, cutting the timeline by up to roughly 30% versus Full, for Class B, C and D alike.

Conditions: the product must have completed MDA’s full CAB conformity assessment and MDA review (excluding differently classified products and Class D with ancillary medicinal products), and the submission must include the MDA certificate, the CAB certificate of conformity and the full Abridged dossier required by GN-15.

Q21. How does Thailand’s HSA Reliance Route work?

This is a one-way channel created by the Thai FDA in 2020 – Thailand relying on Singapore – and it is now a standing route. It began as a twelve-report pilot in September 2020, launched formally at the end of 2021 for high-risk products, and from 1 June 2022 covers Thai classes 2, 3 and 4 (corresponding to Singapore B, C and D) plus IVDs.

The benefit is the waiver of the specialist review step: review time falls from about 150 working days to about 60, and the specialist review fee of roughly THB 53,000 is waived – typically one to three months saved.

Three conditions matter: the CSDT filed in Thailand must be identical to the version filed with HSA, including subsequent changes; the Singapore Registrant must sign a consent form authorising HSA to share its evaluation file with the Thai FDA; and the applicants on both sides need to coordinate.

Thailand also maintains a separate reference-agency list: the five GHTF founding members (US, EU, Japan, Canada, Australia), WHO prequalification for IVDs, and Singapore HSA. Devices approved by the GHTF five can use the Concise Evaluation Route, provided the approval is at least one year old and the trade name, intended use, labelling, instructions and packaging are identical. HSA approvals, by contrast, are only usable through the Thailand-Singapore reliance programme, not the Concise route.

Q22. Is there a Malaysia-Thailand programme?

Yes, and it is fully operational – the point most often got wrong. MDA and the Thai FDA issued a joint announcement on 1 May 2026 bringing their Medical Device Regulatory Reliance Programme into full effect with no expiry date. The sequence was a confidentiality agreement signed at the 29th GHWP annual meeting in Bangkok on 4 December 2025, a three-month pilot from 1 February to 30 April 2026, then full implementation.

Scope: Malaysian Class B, C and D devices, corresponding to Thai classes 2, 3 and 4. Thai class 1 and Malaysian Class A are excluded.

Three hard conditions, any of which voids eligibility:

1. The MDA approval must be a full registration – devices approved through special notification routes, or exempted from quality, performance and safety assessment, are excluded;
2. The product presented to the Thai FDA must match the MDA-approved version exactly: trade name, model identifiers, product codes, intended use, indications, labelling, accompanying documents and packaging. Any mismatch returns the file to full review;
3. A complete CSDT is still required – reliance waives the external expert evaluation, not the documentation.

Note the asymmetry: the Thailand-Malaysia route only removes external expert evaluation and does not apply the Abridged pathway as a whole, so its time gain (about 150 to 120 calendar days) is smaller than Thailand’s HSA Reliance Route (about 150 to 60 working days plus the fee waiver). In short, Singapore remains the fastest way into Thailand, while Malaysia can be reached fastest through Thailand, Singapore or another recognised agency.

Q23. What about adding Malaysia to Thailand’s reference-agency list?

That is a separate track, and it is not yet in force. On 10 July 2026 the Thai FDA opened a ministerial draft for comment, proposing to add MDA to its reference-agency list – the same framework HSA sits in – with the consultation running from 9 July to 7 August 2026. If adopted, MDA-approved class 2, 3 and 4 devices could use an accelerated channel similar to the one for HSA products. As of publication, no formal adoption has been announced and the eligibility conditions, documentation and timelines remain unpublished. Treat it as a parallel track to the bilateral programme and keep watching for the official notice.

Q24. The four mechanisms side by side

Q25. What is the optimal three-country strategy?

For most exporters the strongest sequence starts in Singapore, because an HSA listing opens more doors afterwards than any other ASEAN approval:

Alternatives for companies already established in Malaysia: use the MDA certificate for Thailand under the bilateral programme (external expert evaluation waived), and for Singapore under Abridged (about 30% shorter). If Malaysia is the only target and a Thai approval already exists, the MDA Verification Route applies directly.

The discipline that decides everything: every reliance mechanism is conditional on version identity. Trade name, model, intended use, labelling, packaging and CSDT content must match the source approval. A single inconsistency voids reliance, usually without a remedy other than reverting to full review. This is precisely why one Registrant coordinating all three filings beats three independent agents.

6. Post-market obligations (Q26)

Q26. What continuing obligations apply, and what about unregistered devices, labels and advertising?

Continuing duties for the Registrant and licensed dealers:

1. Adverse events: incidents causing death or serious injury must be reported to HSA through SHARE within 15 calendar days of becoming aware;
2. FSCA and recalls: HSA must be notified of field safety corrective actions and recalls, graded by severity (GN-10);
3. PSUR: Class C and D devices require periodic safety update reports, normally every two years;
4. Safety-alert monitoring, annual retention fees and licence renewals.

• Special Access Route: unregistered devices can lawfully enter Singapore in four cases – import for re-export (S$280), non-clinical use (S$280), application by a qualified medical practitioner for a patient (S$168), and application by a licensed healthcare institution (S$390), each taking about 14 working days;
• Labelling: Singapore requires English labels with product name and model, manufacturer and Registrant details, country of origin, batch or serial number, expiry and storage conditions, and accepts compliant e-IFU. Thailand requires Thai labels and Malaysia English or Bahasa Malaysia – a three-country programme therefore needs country-specific label versions, and Thailand’s identity requirement makes label control critical;
• Advertising: all three countries regulate device advertising, and Thailand requires prior approval for consumer-facing advertising;
• Connected devices: Singapore launched the voluntary CLS(MD) cybersecurity labelling scheme in October 2024, with four rating levels and a maximum three-year validity – worth building into the market strategy.

GRZAN operates its own subsidiary in Singapore and can act as the local Registrant, giving manufacturers clear ownership of their certificates and the ability to sign the consent form Thailand’s HSA Reliance Route requires. Our scope covers Registrant services, Dealer’s Licence and GDPMDS readiness, full HSA filings in SHARE, CSDT authoring, coordinated Singapore-Malaysia-Thailand programmes – extended to Indonesia, Vietnam and the Philippines – and post-market maintenance including vigilance, change notifications, retention and PSUR.

Compiled from HSA, MDA and Thai FDA regulations, announcements and fee schedules current at the date of publication. The proposal to add Malaysia’s MDA to Thailand’s reference-agency list remained a draft at the time of writing; always confirm against the latest official notices.